Vincent Alcazer
Vincent Alcazer is an expert in Hematology at Hospices Civils de Lyon (France). Vincent Alcazer has authored 70 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 7 of them ongoing. SLR score: 474 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2014 - 2026
Number : 70
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study. PMID 42242261 — research design, bone marrow, blood, fibrosis, neoplasms, biopsy, machine learning, diagnosis, learning, artificial intelligence, primary myelofibrosis, hematologic diseases | Lancet Haematol | 2026 | 0 |
| Shrouded in a starry sky: a case of AML-MRC with KMT2A amplification mimicking Burkitt-like morphology. PMID 42241038 — hematology | Blood | 2026 | 0 |
| HLA diversity is associated with TKI response and treatment-free remission in chronic myeloid leukemia. PMID 41246448 — dasatinib, leukemia, leukemia, myeloid, alleles, therapeutics, leukemia, myelogenous, chronic, bcr-abl positive | Hemasphere | 2025 | 2 |
| The Pivotal Role of Immune Functional Assays in Deciphering Immune Function Alterations. PMID 40796210 — cells, genes, microscopy, electron, scanning transmission, sepsis | Clin Exp Immunol | 2025 | 0 |
| Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model. PMID 40394210 — cells, genes, lymphoma, neoplasms, leukemia, azacitidine, genes, p53, apoptosis, t-lymphocytes, mutation, heterografts, tumor microenvironment, t-lymphocytes, helper-inducer, gene expression, lymphoma, t-cell | Leukemia | 2025 | 0 |
Clinical Studies 10
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia 2023-504865-21-00 — thrombocythemia, essential, safety, thrombocytosis, therapeutics, hydroxyurea | Phase 3 | Active not recruiting | 2024 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia 2023-505232-36-00 — thrombocythemia, essential, safety, thrombocytosis, therapeutics, hydroxyurea | Phase 3 | Active not recruiting | 2024 |
| A Phase 1 Study of JNJ 88549968 a T cell Redirecting Antibody for CALR mutated Myeloproliferative Neoplasms 2023-505584-36-00 — cells, neoplasms, t-lymphocytes | Phase 1 | Recruiting | 2024 |
| A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor na ve myelofibrosis and moderate thrombocytopenia 2024-511309-47-00 — safety, janus kinase inhibitors, primary myelofibrosis, thrombocytopenia | Phase 2 | Recruiting | 2024 |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib NCT07623161 — injections, safety, anemia, pharmaceutical preparations, drug therapy, therapeutics, primary myelofibrosis | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map